After mephedrone became an illegal drug in UK, users are waiting for infrormation from friends or internet about the next legal high, however risky.

Research published online today in the journal Addiction shows that after taking mephedrone, users showed impaired working memory as well as the typical stimulant drug effects of euphoria, self confidence and buzzing.
While intoxicated, they also experienced marked craving for mephedrone and typically binged on the drug, taking it repeatedly for an average of eight hours. When drug-free, this group showed higher levels of depression and poorer long term memory compared to controls using drugs other than mephedrone.
When asked what factors might influence them to try a new legal high, the same users said they would be drawn to a new drug that was pure and had few short-term or long-term harms. While they would be attracted by positive reports from friends and on the Internet, lack of scientific research on the drug and its legal status were less important factors.
Mephedrone has been the most publicized 'legal high' in recent years, but there are many new compounds currently emerging on Internet markets. In 2010, 41 new substances were detected in the EU, compared with 24 in 2009 and 13 in 2008. Of those 41 new substances, 15 are synthetic stimulants, just like mephedrone. One of these may become the new 'legal high' that current mephedrone users want.
Says lead researcher Tom Freeman of University College London, "Drug users today are attracted to new substances that are pure and have few adverse effects. Lack of scientific research on the effects and risks of new legal highs might explain why young people rely on subjective reports from friends or the Internet when deciding whether to try a new substance. Internet reports may be biased and offer an opportunity for drug vendors to promote their products. As well as encouraging new research, an important harm reduction strategy is for the media and advice websites such as FRANK to provide balanced and up-to-date information on these drugs."
Advertisement
Source-Eurekalert